EVOLUTION® NitrX™

  • Research type

    Research Study

  • Full title

    Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur with Cruciate Sacrificing Insert

  • IRAS ID

    303535

  • Contact name

    DeAnne Hart

  • Contact email

    deanne.hart@ortho.microport.com

  • Sponsor organisation

    MicroPort Orthopedics Inc.

  • Clinicaltrials.gov Identifier

    NCT04816773

  • Duration of Study in the UK

    13 years, 0 months, 1 days

  • Research summary

    This study is conducted to evaluate the safety and effectiveness of MicroPort Orthopaedics' (MPO) primary total knee systems (EVOLUTION® NitrX™). In up to 5 investigational sites, newly or previously implanted subjects will be prospectively followed up. The EVOLUTION® NitrX™ system consists of three components and each of these components will be assessed for component survivorship at 1, 3, 5, 7 and 10 years. In total, 150 primary total knee replacements with EVOLUTION® NitrX™ components will be performed. Subjects will have to visit the hospital 6-7 times based upon timing of implantation at enrollment; Screening, Year 1, Year 3, Year 5, Year 7 and Year 10. Secondary objectives include to assess functional scores, subject satisfaction with their total knee replacement procedure, radiography images and safety and tolerability of the system. The study duration will be 13 years, including a 36 month enrollment period and 10 years of follow-up.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    21/NW/0323

  • Date of REC Opinion

    20 Dec 2021

  • REC opinion

    Further Information Favourable Opinion